China once again reiterated its opposition to Japan's release of nuclear-contaminated wastewater from the crippled Fukushima Daiichi Nuclear Power Plant into the Pacific Ocean, calling for the ...
16don MSN
(Stefan Rousseau/Pool Photo via AP, File) FILE - This aerial view shows the Fukushima Daiichi nuclear power plant in Fukushima ... (Kyodo News via AP, File) FILE - Protesters tear up a giant Japanese ...
The regulator did not flag problems with the ADC’s safety or efficacy data. Tuesday’s readout comes soon after the end of the 2024 World Congress on Lung Cancer, where Daiichi Sankyo reported ...
On August 28, 2023, a Chinese military blogger rented a billboard in Times Square to broadcast the dangers of contaminated water from the Fukushima Daiichi nuclear power ... follow" and images of the ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...
Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology, a ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback